78.3 🩺 內科專科考前版

78.3.0.1 📌 䞀頁重點

  • 22E: ADC expansion, tumor agnostic, immunotherapy combinations, oligometastatic SBRT
  • Taiwan: 健保 targeted/immuno 絊付 expanding

78.3.0.2 🌟 Pearls (10)

  1. ADC (antibody-drug conjugate): T-DXd (HER2-low breast), sacituzumab (TNBC), enfortumab (urothelial), polatuzumab (DLBCL)
  2. Tumor agnostic: 5+ approvals (pembrolizumab MSI-H/TMB-H, larotrectinib, dabrafenib, selpercatinib)
  3. Oligometastatic SBRT improves OS in selected
  4. Neoadjuvant immunotherapy changing paradigm (NSCLC, melanoma)
  5. CDK4/6 + endocrine standard for HR+ advanced breast
  6. Antibody-drug conjugate ADC > chemo in HER2-low breast (DESTINY-Breast)
  7. CAR-T 4-1BB vs CD28 signaling differences
  8. Bispecific Ab (BiTE) outpatient option for hematologic
  9. mRNA cancer vaccines in trials
  10. Theranostics: 177Lu-PSMA for prostate, 177Lu-DOTATATE for NET

78.3.0.3 📍 Taiwan

  • 健保 immunotherapy 倚 cancer
  • 健保 targeted therapy expanding
  • 健保 ADC for breast
  • 健保 CAR-T 限制
  • 健保 CGP NGS
  • 健保 177Lu-DOTATATE 神經內分泌瘀

78.3.0.4 🎓 內專重點

  1. 治療意圖
  2. Chemo 5 類 + toxicity
  3. Targeted therapy by mechanism
  4. Immunotherapy + irAE
  5. CAR-T + CRS
  6. Tumor agnostic (22E)
  7. ADC era

⚠ AI 草皿。